Century Therapeutics Inc
IPSC
|
$3.05
-1.29%
-1.64%
66K
|
Professional, Scientific, and T...
(0.0% 1d) (-23.9% 1m) (0.7% 1y) (0.0% 2d) (0.0% 3d) (7.4% 7d) (-41.74% volume)
Earnings Calendar: 2024-03-14
Market Cap: $ 197,694,482
https://www.centurytx.com/
Sec Filling | Patents | 102 employees
(US) Century Therapeutics, Inc. specializes in adult stem cells to develop curative cell therapy products for cancer that overcome the limitations of first generation cell therapies as well as provides testing and research services.
t-cell cancer
add to watch list Paper trade email alert is off
Press-releases
Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade Therapeutics
Published: 2024-04-11 (Crawled : 11:00) - globenewswire.com
IPSC | $3.05 -1.29% -1.64% 66K
|
Professional, Scientific, and T...
|
| O: 3.39%
H: 11.53%
C: 2.02%
disease million pipeline acquisition expansion therapeutics
Century Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Published: 2024-04-08 (Crawled : 20:00) - globenewswire.com
IPSC | $3.05 -1.29% -1.64% 66K
|
Professional, Scientific, and T...
|
| O: -1.59%
H: 8.87%
C: 7.8%
association cancer cell research preclinical for meeting technology therapeutics therapy platform
Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors
Published: 2024-03-25 (Crawled : 11:00) - globenewswire.com
SGMT | News | $4.03 0.5% 0.25% 300K
|
Health Technology
|
| O: 6.65%
H: 18.5%
C: 8.52%
IPSC | $3.05 -1.29% -1.64% 66K
|
Professional, Scientific, and T...
|
| O: 0.0%
H: 1.58%
C: -9.48%
RPHM | $1.69 -2.87% -3.57% 180K
|
Professional, Scientific, and T...
|
| O: -1.81%
H: 4.91%
C: 2.45%
XOMA | $25.82 1.33% 0.51% 7.3K
|
Health Technology
|
| O: 1.09%
H: 3.51%
C: -4.27%
MIRM | $24.17 1.51% 1.49% 250K
|
Health Technology
|
| O: 0.0%
H: 1.61%
C: 0.04%
Century Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
Published: 2024-03-19 (Crawled : 11:00) - globenewswire.com
IPSC | $3.05 -1.29% -1.64% 66K
|
Professional, Scientific, and T...
|
| O: 1.26%
H: 1.25%
C: -0.21%
conference cell therapeutics therapy
Century Therapeutics Reports Full Year 2023 Financial Results and Provides Business Updates
Published: 2024-03-14 (Crawled : 12:00) - globenewswire.com
IPSC | $3.05 -1.29% -1.64% 66K
|
Professional, Scientific, and T...
|
| O: -0.41%
H: 0.0%
C: -6.82%
business year therapeutics financial results
Century Therapeutics Announces Six Upcoming Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Published: 2024-03-05 (Crawled : 23:00) - globenewswire.com
IPSC | $3.05 -1.29% -1.64% 66K
|
Professional, Scientific, and T...
|
| O: 2.59%
H: 16.28%
C: 14.68%
six association cancer research meeting therapeutics
Century Therapeutics to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
Published: 2024-02-01 (Crawled : 12:00) - globenewswire.com
IPSC | $3.05 -1.29% -1.64% 66K
|
Professional, Scientific, and T...
|
| O: -1.4%
H: 10.9%
C: 0.24%
conference therapeutics
Century Therapeutics Presents Initial Data from CNTY-101 Phase 1 ELiPSE-1 Trial Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion™ Edits
Published: 2023-12-09 (Crawled : 20:20) - globenewswire.com
IPSC | $3.05 -1.29% -1.64% 66K
|
Professional, Scientific, and T...
| Email alert
Add to watchlist
cnty-101 trial therapeutics potential
Century Therapeutics Receives FDA Clearance of IND Application for CNTY-101 in Systemic Lupus Erythematosus
Published: 2023-12-06 (Crawled : 12:30) - globenewswire.com
IPSC | $3.05 -1.29% -1.64% 66K
|
Professional, Scientific, and T...
|
| O: 8.23%
H: 33.92%
C: 25.73%
cnty-101 fda lupus clearance application therapeutics
Century Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data from Phase 1 ELiPSE-1 trial of CNTY-101 in Relapsed or Refractory B-cell Lymphomas and Planned Phase 1 Study in Systemic Lupus Erythematosus
Published: 2023-12-06 (Crawled : 12:30) - globenewswire.com
IPSC | $3.05 -1.29% -1.64% 66K
|
Professional, Scientific, and T...
|
| O: 8.23%
H: 33.92%
C: 25.73%
cnty-101 conference lupus lymphomas trial therapeutics study
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 73% | 27% |
Top 10 Gainers
MTTR | News M | $4.8 175.86% 63.6% 71M
|
AGBA | $2.5 100.0% 56.6% 200M
|
Finance
MLEC | $2.47 76.43% 42.62% 78M
|
n/a
NUWE | $0.334 29.96% 40.99% 2.5M
|
Manufacturing
EDBL | News | $6.26 66.49% 40.13% 16M
|
ATGL | $2.86 46.25% 32.8% 180K
|
ONFO | $0.6088 38.68% 27.74% 7.3M
|
n/a
VIVK | $1.43 33.65% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.7M
|
SDIG A | $3.64 35.32% 26.0% 990K
|
Last 48 Hours Insiders Buying
MCFT P 26039 | $21.5 1.9% 1.86% 110K
|
Consumer Durables
|
00:00
YORW P 29 | $35.42 1.0% 1.02% 66K
|
Utilities
|
19:01
VUZI P 14500 | $1.35 11.57% 10.37% 840K
|
Electronic Technology
|
17:00
BANF P 256 | $91.28 2.24% 2.18% 150K
|
Finance
|
15:30
RMCF | $3.57 0.56% 0.28% 11K
|
Consumer Non-Durables
|
20:10